New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.

Efalizumab is a humanized anti-CD11a monoclonal IgG(1) antibody approved for the treatment of moderate-to-severe plaque psoriasis. This case report describes two cases of new-onset debilitating psoriatic arthritis in patients with plaque psoriasis on long-standing efalizumab therapy, despite the fact that their skin disease was in remission. Although during the clinical trials, involving over 2,700 study subjects, arthralgia was seen only at a rate of 1-2% higher than in those subjects receiving placebo, the cases presented here are interesting in that it appears that efalizumab treatment 'uncoupled' the psoriatic arthritic component from the cutaneous disease. It can be speculated that a possible mechanism for efalizumab-induced psoriatic arthritis is related to the blockade of regulatory T cells from joint tissue.
AuthorsWendy A Myers, David Najarian, Alice B Gottlieb
JournalThe Journal of dermatological treatment (J Dermatolog Treat) Vol. 17 Issue 6 Pg. 353-4 ( 2006) ISSN: 0954-6634 [Print] England
PMID17853308 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Immunologic Factors
  • efalizumab
  • Adult
  • Aged, 80 and over
  • Antibodies, Monoclonal (adverse effects)
  • Arthritis, Psoriatic (chemically induced)
  • Female
  • Humans
  • Immunologic Factors (adverse effects)
  • Psoriasis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: